Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

VJVirtual | Results from VIT-0910: temozolomide plus vincristine and irinotecan in refractory rhabdomyosarcoma

Julia Chisholm, PhD, FRCPCH, The Royal Marsden NHS Foundation Trust, describes the VIT-0910 study, a European randomized Phase II trial, in which efficacy and safety of vincristine and irinotecan combination therapy with or without temozolomide was assessed in patients with relapsed or refractory rhabdomyosarcoma. Results suggest that the addition of temozolomide improved the efficacy of chemotherapy in patients with relapsed rhabdomyosarcoma, with vincristine, irinotecan, and temozolomide together being considered as standard treatment going forward. Dr Chisholm also explains that the addition of regorafenib, a tyrosine kinase inhibitor, to vincristine and irinotecan combination therapy is also being investigated in an ongoing study, with promising results obtained from a Phase I trial. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.